Clinical data, manufacturing readiness, supply continuity, market access, and physician confidence now play an increasingly important role in determining biosimilar success. In a market where analytical comparability alone is no longer enough, organizations must connect decisions, evidence, and execution across the product lifecycle to convert biosimilarity into sustained market value.

Drawing on industry trends, evolving regulatory requirements, and leading practices, this point of view explores how organizations can move beyond development milestones to build the capabilities needed for long-term competitive advantage.

Strategic Imperatives

  • Understand why the next phase of biosimilar competition will be won or lost after approval.
  • Explore how connected execution improves development, manufacturing, supply, and commercialization outcomes.
  • Learn why success increasingly depends on turning lifecycle experience into reusable organizational knowledge.
  • Understand how leading organizations are transitioning from fragmented execution to integrated, data-driven market leadership.